Feature Story | 19-Nov-2026

The surprising cancer connection at the heart of Alzheimer’s

Howard Hughes Medical Institute

Key Takeaways:

  • HHMI Investigator Chris Walsh discovered that cancer-driving mutations concentrated in microglia — the brain’s immune cells — may contribute to the inflammatory cascade underlying Alzheimer’s disease.
  • The same mutations Walsh found in Alzheimer’s brains also appear in patients’ blood, pointing toward both a new diagnostic tool and a potential treatment strategy using cancer drugs already in clinical use.
  • In patients with Alzheimer’s, ALS, and frontotemporal dementia, neurons carry DNA damage that should take centuries to accumulate in normal brain, suggesting a shared mechanism across neurodegenerative diseases that is distinct from normal aging.

People say “the body keeps score” — but it might be more accurate to say our neurons do. In healthy people, neurons accumulate about 17 single-nucleotide variants each year, a pattern that holds from birth through a person’s final years, according to research from HHMI Investigator Chris Walsh and others.

“It’s a tremendously precise clock,” he explains. Like rings inside a tree, a neuron’s genome can reveal a person’s age with remarkable precision — unless that person has neurodegenerative disease.

When Walsh examined postmortem brain tissue from patients with Alzheimer’s, ALS, and other dementia-causing conditions, he found neurons carrying thousands of mutations that would have taken centuries to accumulate in normal brain. Their neuronal clocks weren’t just broken; they were smashed. But what caused all this damage?

Looking to Cancer for Answers About Alzheimer’s

Walsh and his lab at Boston Children’s Hospital had already made an unusual finding that seemed relevant: common cancer mutations — RAS variants — turning up in neurons that rarely form tumors. Then, a paper by another research group caught his attention: in a rare disease, patients carried cancer-related mutations in another RAS pathway gene specifically in their microglia, the brain's immune cells, and developed dementia. If cancer-like mutations could drive microglia to cause dementia in this rare condition, Walsh wondered, could they be doing the same thing in Alzheimer's disease?

In his next study, Walsh examined postmortem brain tissue from Alzheimer’s patients, treating it as he would a tumor biopsy, screening for cancer-driving mutations. They were present in spades, and particularly concentrated in the microglia. But Walsh notes that other scientists have found these same cancer-driver mutations across the body, in skin and organ tissue alike.

“Considering how ubiquitous these mutations are, cancer is actually rarer than we might expect,” he says. “It’s not enough to have these mutations; they have to occur in just the right cell, in a particular sequence, to become cancer.”

In a brain already accumulating amyloid — another hallmark of Alzheimer’s — these mutated cells seemed to thrive. According to Walsh, the inflammation associated with amyloid accumulation acts as a selective pressure: only the toughest cells survive. The cancer mutations make microglia exactly that — tougher, and harder to kill off. Over decades, that pressure builds, driving mutations across more and more cells, until they become — as Walsh calls them — “angry murderers” that attack healthy neurons, eventually evolving into full-fledged Alzheimer’s.

His lab also found these same cancer-driving mutations present in patients’ blood, suggesting the mutations begin in the body and travel to the brain via cells that can cross the blood-brain barrier. The finding may help explain why exercise is a well-documented behavioral protection against Alzheimer’s. Recent animal studies have shown that more physically active laboratory animals carry fewer of these mutations in their blood — which, if Walsh’s model is correct, would mean fewer mutation-carrying cells migrating into the brain, and less of the inflammation that drives disease.

When Neuronal DNA Breaks Down

That selection process explains why microglia turn hostile — but not why the neurons themselves are dying. For that, Walsh’s lab had to look at the specific mechanisms breaking down within the neurons.

They found a second kind of damage — distinct from the accelerating single-nucleotide variants — in the form of frequent, brief insertions and deletions of DNA called indels. They were concentrated in coding regions, promoters, and enhancers, where they could do the most harm. Tellingly, these indels appeared only in the cerebral cortex, which is ravaged by disease, and not in the cerebellum, which is spared, suggesting a direct link to neurodegeneration rather than a byproduct of aging. Walsh found the same pattern across Alzheimer's, ALS, and frontotemporal dementia, pointing to a shared underlying mechanism. His suspicion is that indels occur commonly but are usually repaired efficiently in healthy individuals; in neurodegeneration, that repair process breaks down.

“When we think of Alzheimer’s, we often think about people carrying risk genes,” Walsh explains. “But this suggests that the genome’s evolution might be just as important as the genes we’re born with.”

A New Map for Treatment

The presence of cancer-driving mutations in blood opens the door to new clinical possibilities. Someday, a simple blood test could potentially flag Alzheimer’s risk years before symptoms appear — earlier and less invasively than current diagnostic tools.

Walsh also suspects it may be more effective to target these mutations directly — rather than clearing amyloid, as many current drugs attempt to do. His findings suggest that by the time a patient is symptomatic, the inflammatory process has already become self-sustaining: the amyloid has done its damage, and clearing it may be like closing the barn door after the horse has bolted.

The tools for his treatment strategy may already exist. The same RAS-pathway mutations Walsh found concentrated in Alzheimer’s microglia are the targets of cancer drugs already in clinical use. They are far from proven as a treatment for Alzheimer’s — but for a disease that has resisted treatment for decades, existing drugs are an exciting place to start.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.